Marianne De Backer, MSc, PhD, MBA

Passionate about making a difference for patients.

[Gladstone Institutes @GladstoneInst]

Congrats to Foundation Board Member Marianne De Backer (@MDDBacker) on her new appointment!
https://t.co/Wt8UwuxXlf

[Vir Biotechnology @Vir_Biotech]

Legendary biotech leader George Scangos, PhD, today announced his retirement after a storied career delivering impactful medicines to patients worldwide. With his support, Vir's BOD unanimously appointed Marianne De Backer, MSc, PhD, MBA, as his successor. https://t.co/nVgICTDfqX

[Bayer | Pharmaceuticals @BayerPharma]

+++ Breaking #NEWS +++
@Bayer today announced the #acquisition of the global strategic imaging AI platform and solutions provider @Blackford Analysis Ltd.
Learn more: https://t.co/445BvCkQZH

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

Adding Blackford and its AI technology to our radiology portfolio secures Bayer an excellent position in the fastest growing segment within the overall global radiology industry https://t.co/N4tuaRRHpZ

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

Fun to attend ⁦@statnews⁩ podcast #thereadout live!

[Stefan Oelrich @stefanoelrich]

Mit dieser Haushaltsentscheidung entsteht ein gutes Stück mehr Zukunft für den Standort Deutschland und Hoffnung für viele Patienten überall auf unser Welt.

[Eric Topol @EricTopol]

🆕 @NatureMedicine
Heart manifestations of #LongCovid
A prospective MRI study of 346 people with mild Covid, and controls, demonstrated myocardial inflammation at 3 months, worse w/ symptoms, and edema at ~1 year
by @v_puntmann and colleagues @GoetheCVI
https://t.co/TjrAJphYCh

[Bayer | Pharmaceuticals @BayerPharma]

+++ #news +++
We are proud to announce that @ask_bio a subsidiary of @Bayer, reached a significant milestone with their investigational gene therapy for #HuntingtonsDisease, moving one step closer to potentially changing how this disease is tackled today!
https://t.co/qakr3E0Y5T

[Bayer | Pharmaceuticals @BayerPharma]

+++ #News #TeamBayer +++
Bayer to present data from cardiovascular portfolio at #ESC2022:
https://t.co/bAWlvXE41f

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

@HyattConcierge Dear Mr. Groen,
Looking forward to arriving tomorrow! 
One question, it says on the website that self-parking is subject to availability. My husband has an Achilles tendon rupture and walks with crutches. Is it possible to have a parking spot reserved? 
Thank you,
M. De Backer

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

@BayerPharma @Bayer @US_FDA New hope for #patients with metastatic hormone sensitive #prostatecancer.

"NUBEQA + docetaxel showing a 32% reduction in the risk of death compared to docetaxel alone and with a proven tolerability profile."

Fruit of our partnership with
Orion Corporation

#teambayer

[Bayer | Pharmaceuticals @BayerPharma]

+++ #NEWS +++
@Bayer announces @US_FDA approval for an additional indication for its therapy treating metastatic hormone-sensitive #ProstateCancer (mHSPC), advancing Bayer’s commitment to the prostate cancer community.
#TeamBayer
Learn more: https://t.co/bAWlvXE41f

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

@NanoGagliato 2022 is a wrap!
It was a fantastic (small) gathering of global leaders and scientists, fully engaging the local Gagliato community, teaching 80+ children about DNA/RNA/nanomedicine and much more
https://t.co/2s30HgwbQg
#STEM #nanomedicine #RNA

[Leaps by Bayer @LeapsByBayer]

Proud to announce our newest investment in @ReCodeTx, a company pioneering game-changing #precisionmedicine for underserved patients with #geneticdiseases, like #cysticfibrosis. Learn about their technology: https://t.co/WLyXSEJZyG

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

Join @McKinsey’s session live now about funding transformational platforms to learn more about @BayerPharma’s external innovation strategy: https://t.co/NStFOxiPaZ

#bio2022 #limitlesstogether #collaboratetocure #teambayer

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

Getting ready to discuss how to cultivate #innovation post-acquisition via our arm’s length model with Jeff Hatfield from @VividionRx.
#BIO2022 #collaboratetocure #teambayer #limitlesstogether

[Marianne De Backer, MSc, PhD, MBA @MDDBacker]

Congratulations to @Evotec and the @BayerPharma BD&L/OI team, especially Christoph Huwe, for winning the @ASAP_Global Alliance Excellence award! This recognition is a testament to our #collobaratetocure approach to partnerships.

[ArrowheadPharma @ArrowheadPharma]

We entered into a license agreement with a new joint venture, Visirna Therapeutics, Inc. #Visirna will develop and commercialize four of Arrowhead’s investigational #RNAi therapeutics for #cardiometabolic diseases in Greater China. Learn more here: https://t.co/ZJYgnoIUUf $ARWR

[ArrowheadPharma @ArrowheadPharma]

The VISTA program is a series of mid to late-stage clinical trials for those with #CardiovascularDiseases. With investigational #RNAi candidate ARO-ANG3, we hope to provide a potential treatment. Learn more about our three ongoing VISTA studies here: https://t.co/VIupLkiyDL $ARWR

[Viralgen @ViralgenVC]

Our new commercial manufacturing facility opened last year added 300,000 square feet of capacity, with each of the 9 suites offering up to 2,000L scales. It also houses in-house fill and finish QC labs and warehousing that makes #Viralgen the largest #AAV CDMO worldwide. 🧪🔬